A 3-year randomized, open label, multi-centre investigator driven study comparing de novo enteric coated mycophenolate sodium with delayed onset everolimus, both arms in combination with cyclosporin (using C2 monitoring) and corticosteroids for the prevention of bronchiolitis obliterans syndrome in heart-lung, bilateral lung and single lung transplantation.

Trial Profile

A 3-year randomized, open label, multi-centre investigator driven study comparing de novo enteric coated mycophenolate sodium with delayed onset everolimus, both arms in combination with cyclosporin (using C2 monitoring) and corticosteroids for the prevention of bronchiolitis obliterans syndrome in heart-lung, bilateral lung and single lung transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Ciclosporin; Corticosteroids; Everolimus; Mycophenolate sodium
  • Indications Bronchiolitis obliterans; Lung transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Aug 2013 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
    • 21 Apr 2012 3-year results presented at the 32nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 30 Apr 2011 Planned number of patients changed from 240 to 320.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top